Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03266510 · ClinicalTrials.gov registry record · NA

Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function

A NA study, sponsored by Douglas Seals.

Completed
Registry status
NA
Development phase
64
Enrollment target

NCT03266510: Completed NA study, sponsored by Douglas Seals.

NCT03266510 is a NA study that has completed, run by Douglas Seals. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03266510, a NA study, has completed, sponsored by Douglas Seals.

COMPLETED
Registry status
NA
Development phase
64 participants
Enrollment target

Study Summary

The purpose of this study is to assess the efficacy of inspiratory muscle strength training for lowering blood pressure and improving physiological function (vascular, motor, and cognitive) in middle-aged and older adults with elevated systolic blood pressure.

Primary Outcome

Resting blood pressure

Interventions

  • OTHER Inspiratory muscle strength training
  • OTHER Sham training

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2017-11-25
Est. Completion 2020-10-30
Phase NA
Douglas Seals

3 total trials

What the finished NCT03266510 record still lists

NCT03266510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which Inspiratory muscle strength training is the first listed.

NCT03266510 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03266510 about?

NCT03266510 is a clinical study titled "Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function". The purpose of this study is to assess the efficacy of inspiratory muscle strength training for lowering blood pressure and improving physiological function (vascular, motor, and cognitive) in middle-aged and older adults with elevated systolic blood pressure.

What is the current status of trial NCT03266510?

This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2017-11-25. Estimated completion is 2020-10-30.

What interventions are being tested in trial NCT03266510?

The interventions under investigation include: Inspiratory muscle strength training (OTHER), Sham training (OTHER).

Who is sponsoring clinical trial NCT03266510?

This trial is sponsored by Douglas Seals, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03266510's enrollment target sits among peer trials

64 1147th of 2000 higher than 844 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03266510, the US trial registry maintained by the National Library of Medicine. NCT03266510 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.